Shire plc, of Dublin, reported top-line results showing that a four-week randomized, double-blind, parallel-group, placebo-controlled, forced-dose titration, efficacy and safety study met it primary endpoints for both doses of SHP465 (12.5 mg and 37.5 mg), administered once daily, in patients with attention deficit hyperactivity disorder (ADHD).